These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26279362)

  • 1. Leptin in Alzheimer's disease.
    Magalhães CA; Carvalho MG; Sousa LP; Caramelli P; Gomes KB
    Clin Chim Acta; 2015 Oct; 450():162-8. PubMed ID: 26279362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
    Xu BG; Wu X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease.
    Huang HC; Jiang ZF
    J Alzheimers Dis; 2009; 16(1):15-27. PubMed ID: 19158417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S
    Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of Metabolic Disruption in Alzheimer's Disease Pathology.
    Ryu JC; Zimmer ER; Rosa-Neto P; Yoon SO
    Neurotherapeutics; 2019 Jul; 16(3):600-610. PubMed ID: 31270743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
    Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
    Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Potential Link Between Visceral Obesity and Risk of Alzheimer's Disease.
    Al-Kuraishy HM; Al-Gareeb AI; Alsayegh AA; Hakami ZH; Khamjan NA; Saad HM; Batiha GE; De Waard M
    Neurochem Res; 2023 Mar; 48(3):745-766. PubMed ID: 36409447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.
    Kar S; Slowikowski SP; Westaway D; Mount HT
    J Psychiatry Neurosci; 2004 Nov; 29(6):427-41. PubMed ID: 15644984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse models of Alzheimer's disease: the long and filamentous road.
    Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
    Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies.
    McGuire MJ; Ishii M
    Cell Mol Neurobiol; 2016 Mar; 36(2):203-17. PubMed ID: 26993509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.
    Oddo S; Billings L; Kesslak JP; Cribbs DH; LaFerla FM
    Neuron; 2004 Aug; 43(3):321-32. PubMed ID: 15294141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease pathogenesis and therapeutic interventions.
    Parihar MS; Hemnani T
    J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
    Johansson A; Zetterberg H; Håkansson A; Nissbrandt H; Blennow K
    Neurodegener Dis; 2005; 2(1):28-35. PubMed ID: 16909000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease modifying therapy for AD?
    Golde TE
    J Neurochem; 2006 Nov; 99(3):689-707. PubMed ID: 17076654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.